The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•18 June 2026•

2 min read

FDA Approves GSK's Utebzi as First Oral Carbapenem for Urinary Infections

Key Facts

1GSK received FDA approval for Utebzi to treat complicated urinary tract infections (cUTIs).

2Utebzi is the first oral carbapenem antibiotic approved for these conditions.

In a move that strengthens the global standing of British pharmaceutical giants, GSK has received FDA approval for Utebzi to treat complicated urinary tract infections (cUTIs). This drug marks a milestone as the first oral carbapenem antibiotic approved for these conditions, representing a significant shift in treatment protocols. The approval expands GSK's anti-infectives portfolio and provides a new oral treatment option for patients who typically required intravenous therapy.

This regulatory win comes amid intense competition in the sector, with peer AstraZeneca reporting a 12% revenue increase in its biopharmaceuticals division last quarter according to its financial filings. GSK is positioning itself to capture a larger share of the global antimicrobial market, which is projected to grow at a CAGR of 4.5% through 2030 per Grand View Research data. Such approvals are critical for the company to offset revenue gaps from older drugs facing patent expirations.

Regarding market performance, GSK.L shares stood at 1958p (at close June 15, 2026), having reached a session high of 1989p. Traders are monitoring support levels near 1953p to sustain bullish momentum following the news. Looking ahead, investors remain focused on broader UK economic health, noting that recent GDP data showed a slight contraction of -0.1%, making corporate successes like GSK's vital for market sentiment.